Systemic Therapies in Managing Sinonasal Inflammation

Otolaryngologic Clinics of North America

Volumn 43, Issue 3, 2010, Pages 551-563

  DeMarcantonio, Michael A ^a   Han, Joseph K ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Allergy; Aspirin desensitization; Immunotherapy; Inflammation; Leukotriene; Polyp; Sinusitis; Steroid

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN E ANTIBODY; IMMUNOMODULATING AGENT; INTERLEUKIN 5 ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; MEPOLIZUMAB; MONOCLONAL ANTIBODY; MONTELUKAST; OMALIZUMAB; PEPTIDOLEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; PREDNISONE; RESLIZUMAB; ROXITHROMYCIN; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ASTHMA; BRONCHIOLITIS; CHRONIC RHINOSINUSITIS; CLINICAL PRACTICE; CLINICAL TRIAL; DESENSITIZATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENDOSCOPIC SINUS SURGERY; HUMAN; HYPERSENSITIVITY; IMMUNOMODULATION; IMMUNOTHERAPY; LOW DRUG DOSE; NASAL BIOPSY; NOSE POLYP; PARANASAL SINUSITIS; PATIENT SELECTION; REVIEW; RHINOSINUSITIS; RISK BENEFIT ANALYSIS;

ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; DRUG THERAPY; EOSINOPHILS; HISTAMINE ANTAGONISTS; HUMANS; HYDROXYUREA; IMMUNOLOGIC FACTORS; LEUKOTRIENE ANTAGONISTS; OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES; RHINITIS; SINUSITIS; TOSYL COMPOUNDS;

EID: 77953498809     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2010.02.013     Document Type: Review

References (53)

1. Benson V., Marano M. Current estimates from the national health interview survey, 1995 1998, National Center for Health Statistics, Hyattsville (MD), Vital Health Stat 10, No. 199.
2. Pawanker R. Nasal polyposis: an update. Curr Opin Allergy Clin Immunol 2003, 3:1-6.
3. Drake-Lee A.B., McLaughlan P. Clinical symptoms, free histamine and IgE in patients with nasal polyposis. Int Arch Allergy Appl Immunol 1982, 69(3):268-271.
4. Pawankar R., Nanoka M. Inflammatory mechanisms and remodeling in chronic rhinosinusitis and nasal polyps. Curr Allergy Asthma Rep 2007, 7:202-208.
5. Georgitis J.W., Matthews B.L., Stone B. Chronic sinusitis: characterization of cellular influx and inflammatory mediators in sinus lavage. Int Arch Allergy Immunol 1995, 106:416-421.
6. Statham M.M., Seiden A. Potential new avenues of treatment for chronic rhinosinusitis: an anti-inflammatory approach. Otolaryngol Clin North Am 2005, 38:1351-1365.
7. Parnes S.M. The role of leukotriene inhibitors in patients with paranasal sinus disease. Curr Opin Otolaryngol Head Neck Surg 2003, 11:184-191.
8. Jung T.T., Juhn S.K., Hwang D., et al. Prostaglandins, leukotrienes, and other arachidonic acid metabolites in nasal polyps and nasal mucosa. Laryngoscope 1987, 97(2):184-189.
9. Fischer A.R., Rosenberg M.A., Lilly C.M., et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994, 94(6 Pt 1):1046-1056.
10. Parnes S.M., Chuma A.V. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J 2000, 79(1):18-20. 24.
11. Ragab S., Parikh A., Darby Y.C., et al. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001, 31(9):1385-1391.
12. Ulualp S.O., Sterman B.M., Toohill R.J. Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J 1999, 78(8):604-606. 608, 613, passim.
13. Cox G., Ohtoshi T., Vancheri C., et al. Promotion of eosinophil survival by human bronchial epithelial cells and its modulation by steroids. Am J Respir Cell Mol Biol 1991, 4(6):525-531.
14. Lennard C., Mann E., Sun L., et al. Interleukin-1B, interleukin-5, interleukin-6, interleukin-8, and tumor necrosis factor-α in chronic sinusitis: response to systemic corticosteroids. Am J Rhinol 2000, 14(6):367-373.
15. Van Camp C., Clement P.A. Results of oral steroid treatment in nasal polyposis. Rhinology 1994, 32(1):5-9.
16. Hissaria P., Smith W., Wormald P., et al. Short course of systemic corticosteroids in sinonasal polyposis: a double blind, randomized, placebo controlled trial with evaluation of outcome measures. J Allergy Clin Immunol 2006, 118(1):128-133.
17. Krouse J.H., Brown R.W., Fineman S.M., et al. Asthma and the unified airway [review]. Otolaryngol Head Neck Surg 2007, 136(Suppl 5):S75-106.
18. Krouse J.H., Veling M.C., Ryan M.W., et al. Executive summary: asthma and the unified airway. Otolaryngol Head Neck Surg 2007, 136(5):699-706.
19. Ahmad N., Zacharek M. Allergic rhinitis and rhinosinusitis. Otolaryngol Clin North Am 2008, 41:267-281.
20. Batra P.S., Kern R.C., Tripathi A., et al. Outcome analysis of endoscopic sinus surgery in patients with nasal polyps and asthma. Laryngoscope 2003, 113(10):1703-1706.
21. Till S.J., Francis J.N., Nouri-Aria K., et al. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004, 113:1025-1034.
22. Tulic M.K., Fiset P.O., Christodoulopoulos P., et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004, 113(2):235-241.
23. Calderon M.A., Alves B., Jacobson M., et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, 1. CD001936.
24. Amin H.S., LIss G.M., Bernstein D.I. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006, 117:169-175.
25. Wilson D.R., Lima M.T., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005, 60(1):4-12.
26. Leatherman B. Injection and sublingual immunotherapy in the management of allergies affecting the unified airway. Otolaryngol Clin North Am 2008, 41:359-374.
27. Cox L.S., Linnemann D.L., Nolte H., et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006, 117:1021-1035.
28. Simon H.U., Yousefi S., Schranz C., et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997, 158(8):3902-3908.
29. Leckie M.J., ten Brinke A., Khan J., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356(9248):2144-2148.
30. Kips J.C., O'Connor B.J., Langley S.J., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167(12):1655-1659.
31. Bachert C., Wagenmann M., Hauser U., et al. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997, 99(6 Pt 1):837-842.
32. Nelson H.S. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2007, 119:872-880.
33. Gevaert P., Lang-Loidolt D., Lackner A., et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006, 118:1133-1141.
34. Parameswaran N., Pizzichini M., Kjarsgaard M., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360(10):985-993.
35. Halder P., Brightling C., Hargadon B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360(10):973-983.
36. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med 2006, 100:1907-1917.
37. Humbert M., Beasley R., Ayres J., et al. Benefits of omalziumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite available therapy (GINA 2002 step 4 treatment), INNOVATE. Allergy 2005, 60:309-316.
38. Penn R., Mikula S. The role of anti-IgE immunogloblulin therapy in nasal polyposis: a pilot study. Am J Rhinol 2007, 21:428-433.
39. Neil Mason. Correspondence; Source: Amerisourcebergen prescription wholesaler, Sentara pharmacy department, Hospital directory for pricing. October 22, 2009.
40. Szczeklik A., Stevenson D.D. Aspirin- induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003, 111(5):913-921. [quiz: 922].
41. Williams A.N., Woessner K.M. The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. Curr Allergy Asthma Rep 2008, 8(3):245-252.
42. Stevenson D.D., Pleskow W.W., Simon R.A., et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984, 73(4):500-507.
43. Lee J.Y., Simon R.A., Stevenson D.D. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007, 119(1):157-164.
44. Hope A.P., Woessner K.A., Simon R.A., et al. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerated respiratory disease. J Allergy Clin Immunol 2009, 123:406-410.
45. Stevenson D.D. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep 2009, 9:155-163.
46. Rozsasi A., Polzehl D., Deutschle T., et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008, 63:1228-1234.
47. Bucca C., Marsico A., Panaro E., et al. Statins and nasal polyps. Ann Intern Med 2005, 142(4):310-311.
48. Hakamada-Taguchi R., Uehara Y., Kuribayashi K., et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003, 93:948-956.
49. Harvey R., Wallwork B., Lund V. Anti-inflammatory effects of macrolides: applications in chronic rhinosinusitis. Immunol Allergy Clin North Am 2009, 29:689-703.
50. Kawasaki S., Takizawa H., Ohtoshi T., et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998, 42:1499-1502.
51. Yamada T., Fujieda S., Mori S., et al. Macrolide treatment decreased size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000, 14:143-148.
52. Wallwork B., Coman W., Feron F., et al. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope 2002, 112:1827-1830.
53. Wallwork B., Coman W., Mackay-Sim A., et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope 2006, 116:189-193.